SCRI and Bristol Myers Squibb have expanded their collaboration to accelerate patient enrollment and extend access to advanced cancer clinical trials. By leveraging a data-driven strategy, the partnership aims to bring innovative research opportunities to a broader range of communities.
Sarah Cannon Research Institute (SCRI) | 15/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy